Criteria, scores and classifications first: one table per set from the slides, each with a labeled memory aid. Hematology Block Exam, condensed from the Exam 8 study guide. Lectures covered: 46 (cytopenias and hemochromatosis), 49 (hematologic malignancies part I), 50 (hematologic malignancies part II). Each lecture opens with a gold card of what its lecturer stressed (starred; from the lecture recording); every fact still comes from the slides.
| Index | What it measures | Normal |
|---|---|---|
| Mean corpuscular volume (MCV) | Average size of red blood cells | 80–100 fL (femtoliters) |
| Mean corpuscular hemoglobin (MCH) | Amount of hemoglobin in each red blood cell | 27–31 pg/cell (picograms) |
| Mean corpuscular hemoglobin concentration (MCHC) | Hemoglobin relative to the size of each red blood cell | 32–36 g/dL (320–360 g/L) |
| Red cell distribution width (RDW) | Differences in the volume and size of the red cells; healthy cells are about the same size | No number on the slide |
| Hemoglobin and hematocrit (H&H) | Hemoglobin: the amount in the blood. Hematocrit: the percentage of red cells in total blood volume | No number on the slide |
| Initial approach (slide 8): history and physical, then the complete blood count: all three cell lines (red cells, white cells, platelets), look for pancytopenia, read the MCV, and use the reticulocyte index to judge whether the marrow response is adequate. | ||
Size up to 100; weight a month’s worth; concentration just past the month.
100 MCV 80–100 fL (size)A month MCH 27–31 pg/cell, like the days in a month (weight per cell)Past the month MCHC 32–36 g/dL (concentration)
Where it breaks: Red cell distribution width and the H&H have no number on the slide.
| Anemia of chronic disease | Iron deficiency anemia | |
|---|---|---|
| Red cells, hemoglobin, hematocrit | ↓ (mild) | ↓ |
| Mean corpuscular volume | Normal or ↓ | ↓ |
| Mean corpuscular hemoglobin and its concentration | Normal or ↓ | ↓ |
| Red cell distribution width | Varies | ↑ |
| Reticulocytes | Usually ↓ | Varies |
| Serum iron | ↑ or ↓ (slide 27) | ↓ |
| Ferritin | Normal or ↑ | ↓ |
| Total iron-binding capacity (TIBC) | ↓ | ↑ |
| Coexisting iron deficiency (slide 25) | Ferritin <30 ng/mL (67 pmol/L) | — |
| Slide conflict: slide 13 gives anemia of chronic disease a low serum iron and transferrin saturation with a normal or low TIBC; slide 27 gives its serum iron as “↑ or ↓”. TIBC also differs: normal or low on slide 13, ↓ on slide 27 (never above normal on either). Both agree on ferritin (normal or ↑): tell them apart by ferritin with TIBC, never by serum iron alone. Ferritin is an acute phase reactant, so a normal or high ferritin does not exclude iron deficiency (slide 14); order an ESR (erythrocyte sedimentation rate) and/or CRP (C-reactive protein) if inflammation is a concern. | ||
Iron deficiency: the Tank (ferritin) is empty, so more Trucks (TIBC) go out looking. Chronic disease: hepcidin Locks the tank: the Tank is full or normal, and fewer Trucks are sent.
Tank empty iron deficiency: ferritin ↓More trucks iron deficiency: TIBC ↑Tank locked chronic disease: ferritin normal or ↑Fewer trucks chronic disease: TIBC ↓
Where it breaks: The tank says nothing about serum iron in chronic disease (↑ or ↓ on slide 27, low on slide 13), or about the indices and red cell distribution width; “fewer trucks” is slide 27 (slide 13: normal or low TIBC).
| Megaloblastic | Non-megaloblastic | |
|---|---|---|
| Defined as | Macrocytic anemia with megaloblasts (early red cell precursors): macro-ovalocytes, hypersegmented neutrophils | Macrocytic anemia without megaloblasts |
| Causes | Vitamin B12 and folate deficiency | Alcohol (common) or drug; hypothyroidism; liver failure; bone marrow dysplasia |
| Mean corpuscular volume | >100 fL (all macrocytic anemia) | >100 fL, but usually <115 fL |
| Mechanism | Impaired DNA synthesis → nuclear-cytoplasmic asynchrony; granulocytes and megakaryocytes affected to a lesser degree | — |
Macrocytic starts at 100; non-megaloblastic usually stops at 115. The non-megaloblastic causes: Alcohol Hits Liver and Marrow.
100 MCV >100 fL defines macrocytic anemia115 non-megaloblastic causes usually stay below 115 fLAlcohol alcohol (common) or drugHits hypothyroidismLiver liver failureMarrow bone marrow dysplasia
Where it breaks: The megaloblastic column (B12 and folate, megaloblasts, hypersegmented neutrophils, impaired DNA synthesis) is not in the hook.
| Parameter | Megaloblastic anemia (macrocytic, normochromic) |
|---|---|
| Red cells, hemoglobin, hematocrit | ↓ |
| Mean corpuscular volume | ↑ (macrocytosis) |
| Mean corpuscular hemoglobin and its concentration | Normal to slightly ↑ |
| Red cell distribution width | ↑ (anisocytosis) |
| Reticulocytes | Varies |
Big and Uneven: the cells are bigger (MCV up) and of uneven sizes (RDW up); the counts fall and the color stays normal.
Big MCV ↑ (macrocytosis)Uneven RDW ↑ (anisocytosis)Counts fall red cells, hemoglobin, hematocrit ↓Normal color MCH, MCHC normal to slightly ↑ (normochromic)
Where it breaks: Reticulocytes (varies) are not in the hook.
| Parameter | Anemia of chronic kidney disease |
|---|---|
| Red cells, hemoglobin, hematocrit | ↓ |
| Mean corpuscular volume | Normal |
| Mean corpuscular hemoglobin and its concentration | Normal |
| Red cell distribution width | ↑ |
| Reticulocytes | ↓ |
| Primarily, but not completely, from decreased erythropoietin; incidence rises as the glomerular filtration rate falls, almost universal on dialysis (slide 52). Slide 53: a low transferrin saturation may mean iron-restricted erythropoiesis despite a normal or high ferritin. | |
Normal-sized cells with no factory order: the kidney stops sending erythropoietin, so the cells look normal but too few are made.
Normal-sized MCV, MCH, MCHC normalNo factory order reticulocytes ↓ (low erythropoietin)Too few red cells, hemoglobin, hematocrit ↓
Where it breaks: The red cell distribution width is ↑ even though the indices are normal.
| Test | What the slide says | Separates B12 from folate? |
|---|---|---|
| B12 and folate levels | The initial tests for all macrocytic anemias, with a peripheral smear; not very sensitive | — |
| Homocysteine | Metabolism of homocysteine to methionine requires both B12 and folate | No (needs both) |
| Methylmalonic acid (MMA) | Metabolism of L-methylmalonyl CoA to succinyl CoA requires only B12: MMA is elevated in B12 deficiency but NOT folate deficiency | Yes |
| IF PERNICIOUS ANEMIA IS SUSPECTED (slides 48, 50) | ||
| Anti-intrinsic factor antibodies | Sometimes detected; specific but not sensitive | |
| Anti-parietal cell antibodies | May be present; not sensitive or specific | |
| Gastric biopsy | May show chronic atrophic gastritis | |
| Parenteral B12 trial | In reality, a megaloblastic picture that corrects with B12 is the normal diagnostic pathway | |
| Homocysteine and MMA are ordered when the B12 and folate levels are borderline or suspicion continues. Before replacing folate, evaluate for B12 deficiency: the labs may improve while permanent neurologic symptoms worsen (slide 49). | ||
Homocysteine is a shared Home (both vitamins live there); MMA is B12’s alone: “Methylmalonic Means B12 Alone”.
Home homocysteine needs B12 and folate, so it cannot tell them apartAlone MMA needs only B12: up in B12, not folate, deficiencySpecific, not sensitive anti-intrinsic factor antibodiesNeither anti-parietal cell antibodies
Where it breaks: The first-line B12 and folate levels, the gastric biopsy and the B12 trial are not in the hook.
| Item | Slide wording |
|---|---|
| Leukopenia vs neutropenia | Leukopenia = a low total white count; neutropenia is defined by the absolute neutrophil count (ANC) |
| Formula | ANC = white count × (neutrophils + bands)% / 100 |
| Mild | ANC 1,000–1,500 cells/µL |
| Moderate | ANC 500–999 |
| Severe | ANC <500 |
| FEBRILE NEUTROPENIA (slide 60) | |
| Emergency | Fever with ANC <500 (or expected to fall below 500): prompt assessment and empiric antibiotics |
| Immediately | Vitals, targeted examination and cultures; start antipseudomonal therapy without delay |
| Risk | Severity, duration and immune status predict infection risk; profound neutropenia may have subtle findings |
| Escalate to hematology (slide 59) | Persistent or unexplained severe neutropenia, other cytopenias, or an abnormal smear |
Count the Neutrophils AND the Bands, then step down by 500: 1500, 1000, 500. Fever under 500 is a fire alarm: cultures and antipseudomonal antibiotics now.
Neutrophils + bands the percentage that multiplies the white count, / 100Below 1500 mild 1,000–1,500Below 1000 moderate 500–999500 severe <500Fire alarm fever + ANC <500 (or expected): empiric antipseudomonal antibiotics without delay
| Test | In hemolysis |
|---|---|
| Bilirubin (conjugated and unconjugated) | Both likely elevated, unconjugated > conjugated |
| Jaundice | Appears when total bilirubin exceeds 2.0 mg/dL (normal 0.3–1.2 mg/dL) |
| Haptoglobin | DECREASED or absent with intravascular hemolysis (it picks up free hemoglobin) |
| Lactate dehydrogenase (LDH) | A cytoplasmic enzyme, elevated with any cellular lysis |
| Peripheral smear | The hallmark finding: schistocytes (red blood cell fragments) |
| Reticulocyte count | Often the first indication; an unexpected rise, even without anemia or symptoms, should prompt consideration of hemolysis |
| Urinalysis | Some hemoglobin reaches the urine in intravascular hemolysis |
| Workup for a suspected hemolytic anemia (slide 69): complete blood count, reticulocyte count, serum bilirubin, LDH, haptoglobin, urinalysis, peripheral smear review. Extravascular hemolysis (spleen and liver macrophages) is the more common route (slide 66). | |
Broken cells Spill: Bilirubin and LDH go Up, Haptoglobin gets Used up, the Smear shows Shards, and the marrow sends more Retics.
Up bilirubin (unconjugated > conjugated) and LDH elevated2.0 jaundice above total bilirubin 2.0 mg/dLUsed up haptoglobin decreased or absent (intravascular)Shards schistocytes, the hallmarkRetics reticulocytes up, often the first sign
| Category | Examples |
|---|---|
| INTRACORPUSCULAR (intrinsic to the red cell) | |
| Hemoglobinopathies | Sickle cell disease, thalassemia, unstable hemoglobin variants |
| Membrane / cytoskeletal defects | Hereditary spherocytosis, elliptocytosis, stomatocytosis |
| Metabolic abnormalities | G6PD (glucose-6-phosphate dehydrogenase) and pyruvate kinase deficiencies |
| EXTRACORPUSCULAR | |
| Immune-mediated | Autoimmune hemolytic anemia, transfusion reactions |
| Hypersplenism | |
| Mechanical trauma | Shear stress |
| Oxidative stress | G6PD, methemoglobinemia |
| Infection | Malaria, babesiosis |
| Toxin | Snake and insect bites, burns, copper poisoning |
Inside the cell it says “HMM”; from outside a MOTH II attacks it.
H Hemoglobinopathies (inside)M Membrane/cytoskeleton (inside)M Metabolic: G6PD, pyruvate kinase (inside)M Mechanical trauma (outside)O Oxidative stress (outside)T Toxin (outside)H Hypersplenism (outside)I Immune-mediated (outside)I Infection (outside)
Where it breaks: G6PD sits on both sides: a metabolic defect inside the cell (slide 64) and oxidative stress outside it (slide 65).
| Item | Slide wording |
|---|---|
| Consider immediate stabilization if | Hemoglobin <6, a rapid decline, or the patient is unstable; contact the blood bank (will need to find compatible blood) |
| Test | Direct antiglobulin (Coombs) test: positive when the washed red cells carry IgG or complement |
| Treat | Rule out secondary causes; glucocorticoids first (e.g., prednisone 60–100 mg daily); rituximab (anti-CD20); others: immunosuppressants, splenectomy |
| Important note | Increased risk of venous thromboembolism: consider D-dimer and bilateral leg ultrasound; venous thromboembolism prophylaxis for inpatients, consider in outpatients |
| Secondary causes | Viruses (human immunodeficiency virus (HIV), hepatitis, Epstein-Barr virus (EBV), SARS-CoV-2); autoimmune (lupus, rheumatoid arthritis, scleroderma, ulcerative colitis); lymphoproliferative (leukemia, lymphoma, multiple myeloma); pregnancy. Primary is almost always IgG |
Six, Sliding, Shaky: stabilize now. Then Steroids first, then the anti-CD20, and watch for Clots.
Six hemoglobin <6Sliding rapid declineShaky unstable patientSteroids glucocorticoids initiallyAnti-CD20 rituximabClots increased venous thromboembolism risk
Where it breaks: The Coombs test and the secondary causes are not in the hook.
| # | Common trigger (slide 79) |
|---|---|
| 1 | Fava beans |
| 2 | Naphthalene (mothballs) |
| 3 | Antimalarials (the slide names chloroquine; out loud, chloroquine does not carry the same risk) |
| 4 | Nitrofurantoin |
| 5 | Trimethoprim-sulfamethoxazole (Bactrim) |
| 6 | Methylene blue |
| 7 | Phenazopyridine |
| 8 | Quinolones |
| TIMING (slides 81–82) | |
| Lag | Drug-induced hemolysis is acute, of variable severity, with a lag of 2–3 days; no symptoms until exposed to oxidative stress |
| Smear | During an attack: Heinz bodies and bite cells |
| Confirm | A low G6PD level roughly 8 weeks after an attack (the slide asks “Why not during an attack?”) |
| Slide conflict: slide 79 lists “antimalarials (chloroquine, etc)” while the slide 83 table lists chloroquine as safe for class II and III variants. Prof. Ward sided with the table out loud: “don’t just assume all anti-malarial medications carry that same risk.” Some antimalarials trigger hemolysis, not every one; no antimalarial is keyed. | |
Fried Nachos And Nuts Turn My Pee Questionable (dark urine is the symptom).
Fried Fava beansNachos Naphthalene (mothballs)And Antimalarials (some; not chloroquine, per Prof. Ward)Nuts NitrofurantoinTurn Trimethoprim-sulfamethoxazoleMy Methylene bluePee PhenazopyridineQuestionable Quinolones
| Item | Slide wording |
|---|---|
| Genes | 4 alpha globin genes and 2 beta globin genes; the phenotype depends on how many are mutated |
| Silent carrier | α−/αα: the mild end of the range |
| Alpha thalassemia 1 trait | αα/−−: often in Asian ancestry; higher risk of hydrops fetalis |
| Alpha thalassemia 2 trait | α−/α−: more often in African ancestry (mild forms) |
| Far end | Incompatible with life |
| Where alpha is prevalent | Southern China, Malaysia, Thailand, the Mediterranean region |
| LABS (slides 87–88) | |
| Pattern | Generally ↓ hemoglobin, ↓ MCV, ↓ MCH, ↓ reticulocyte index (marrow failure), Coombs negative; iron overload (bold, underlined) |
| Order | Complete blood count, iron studies, reticulocyte count; hemoglobin electrophoresis; gene testing |
| Slide 13: thalassemia gives more microcytosis for its hemoglobin level, with a normal or elevated red cell count. Slide conflict: slide 13 also says thalassemia has a reticulocytosis, while slide 87 gives a ↓ reticulocyte index (marrow failure); the reticulocyte direction is not keyed. Slide 86 places beta thalassemia “generally in patients of African origin”; that ancestry claim is not keyed. | |
Trait 1: both dashes on 1 side of the slash (Asian, hydrops risk). Trait 2: the dashes split over 2 sides (African, mild).
1 side αα/−− = alpha thalassemia 1 trait, Asian ancestry, higher hydrops fetalis risk2 sides α−/α− = alpha thalassemia 2 trait, African ancestry1 dash α−/αα = silent carrier
Where it breaks: The slash rule is about the slide’s notation only; the lab pattern is not in the hook.
| Hemoglobin | Make-up | Behavior |
|---|---|---|
| S (sickle) | Two alpha + two mutant beta globins (α2βS2) | Polymerizes under low oxygen tension → sickle shape |
| C | A different beta globin mutation | Does not polymerize |
| SC (sickle cell SC) | βC with βS (α2βSβC) | Course generally between sickle cell anemia and sickle cell trait |
| F (fetal) | α2γ2 | Normally <1%; 10–20% seems a threshold for decreased severity of sickle cell disease or beta thalassemia (hereditary persistence of fetal hemoglobin) |
| Sickle trait (HbAS) carriers are 90% less likely to have severe malaria; the disease follows the malaria belt (slide 91). | ||
S Sickles, C Can’t, SC sits in the Center, F Fends it off at 10–20%.
Sickles HbS polymerizes at low oxygen tensionCan’t HbC does not polymerizeCenter HbSC: between anemia and traitFends HbF normally <1%; 10–20% lessens sickle cell and beta thalassemia severity
| Period | Slide wording |
|---|---|
| Preconception | Identify parents whose offspring would be at risk |
| Prenatal | Can be done by chorionic villus sampling |
| Neonatal | Now done in all 50 states. Those who test negative or bypass screening usually present within the first two years; symptoms start around 5 months (HbF to HbS transition): failure to thrive, pain, anemia, splenomegaly, chronic infections, swelling of the extremities (vaso-occlusion) |
| Post-natal | No detail on the slide |
| The slide gives a gestational week for chorionic villus sampling; it is not keyed (the periods are). | |
Before you Pair, before you’re Born, as a Baby, and After.
Pair preconceptionBorn prenatal (chorionic villus sampling)Baby neonatal: all 50 states; symptoms around 5 monthsAfter post-natal
| Primary | Secondary | |
|---|---|---|
| Cause (slide 100) | Autosomal recessive: mutated genes that control iron absorption | Excessive iron supplementation, chronic liver disease, anemia |
| Liver biopsy (Prussian blue) | Hepatic accumulation of iron sparing the Kupffer cells until later in the disease | Iron (parenteral iron overload) predominantly in Kupffer cells |
| Treatment (slide 104) | Therapeutic phlebotomy, ferritin-guided follow-up | Treat the cause; chelation when phlebotomy is unsuitable |
| IRON PANEL CUT-OFF (slide 103) | ||
| No iron overload | Ferritin <300 micrograms/L AND transferrin saturation <45% | |
| Ferritin is an acute phase reactant: be cautious and look at the entire lab picture (slide 103). | ||
300 and 45: under both and the tank is not overfull. Primary Passes over the Kupffer cells; Secondary Stuffs them.
300 ferritin <300 micrograms/L45 transferrin saturation <45%Both both under = no iron overloadPasses primary: Kupffer cells spared until lateStuffs secondary: iron mainly in Kupffer cells
| Type | Slide wording |
|---|---|
| Hereditary | Usually X-linked |
| Acquired | Usually with myelodysplastic syndrome |
| Acquired / reversible | Alcohol; drugs (isoniazid, chlorambucil); copper deficiency; hypothermia; lead poisoning |
| MODERN CLASSIFICATION (slide 30) | |
| Two categories | Dyserythropoiesis (hypohepcidinemia); transfusion-dependence (myelodysplastic syndrome, thalassemia) |
| Defining feature (slide 32): ring sideroblasts on bone marrow aspirate (iron-containing mitochondria in a ring around the nucleus); excess total body iron with increased serum iron, transferrin saturation and ferritin. | |
The reversible kind: A Drunk Copper Has Lead.
A AlcoholDrunk Drugs: isoniazid, chlorambucilCopper copper deficiencyHas hypothermiaLead lead poisoning
Where it breaks: Covers the reversible list only; hereditary = X-linked, acquired = myelodysplastic syndrome.
| Item | Slide wording |
|---|---|
| First | Treat the underlying condition (the slide’s arrow: “most important”) |
| Agent | Erythropoietin supplementation (epoetin alfa, Procrit) |
| Hemoglobin | Less than 10 g/dL |
| Anemia due to | Rheumatoid arthritis, inflammatory bowel disease, hepatitis C, zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, myelosuppressive chemotherapy of solid malignancy, chronic kidney disease |
| May require parenteral iron; referral to hematology is not usually needed for anemia of chronic disease. | |
Under Ten, a Real Inflammation Hurts: Zidovudine, Chemo, Kidneys.
Ten hemoglobin <10 g/dLReal rheumatoid arthritisInflammation inflammatory bowel diseaseHurts hepatitis CZidovudine zidovudine therapy in HIVChemo myelosuppressive chemotherapy of a solid malignancyKidneys chronic kidney disease
| When | Expected |
|---|---|
| 3 weeks | Hematocrit back halfway toward normal |
| 2 months | Full return to baseline |
| 3–6 months more | Continue iron after normal values return, to replenish iron stores |
| Not responding | Hematology referral if the diagnosis is not confirmed or there is no response to oral iron (slide 17); parenteral iron if intolerant or refractory (most need 1–1.5 g, slide 21) |
| Ferrous sulfate 325 mg (66 mg elemental iron) once daily or every other day; constipation, so always give at least a prn laxative or stool softener; food reduces side effects but also absorption. Alternate-day dosing is probably best; or ferrous sulfate 44 mg/5 mL (as elemental iron) once daily in the morning, on an empty stomach with a full glass of orange juice (slides 18–19). | |
Halfway in 3 weeks, home in 2 months, then 3–6 months to restock the pantry.
Halfway hematocrit halfway to normal by 3 weeksHome baseline by 2 monthsRestock continue 3–6 months after normal to refill stores
| Population | What changes clinically / care priority |
|---|---|
| Infants | Use neonatal complete blood count ranges; recognize inherited anemias and abnormal newborn screens; coordinate pediatric hematology |
| Child | Assess diet and inherited anemia; consider rare genetic or transfusion-related iron overload; weight-based treatment |
| Adolescent | Heavy menses: check complete blood count and ferritin, treat iron deficiency and control bleeding; support adherence and transition to adult care |
| Adult | Evaluate gastrointestinal or gynecologic blood loss, pregnancy and chronic kidney disease; HFE hemochromatosis usually presents in adults: screen family |
| Elderly | Check iron and B12 deficiency, chronic kidney disease, drugs and marrow disorders (myelodysplastic syndrome); tailor to function, comorbidities and goals |
Screens, Spoons, Periods, Pregnancy, Pills.
Screens infants: newborn screens, neonatal rangesSpoons child: diet, weight-based dosingPeriods adolescent: heavy mensesPregnancy adult: also blood loss, kidney disease, HFEPills elderly: drugs, plus iron/B12, kidney, myelodysplastic syndrome
| Condition | Patient education / referral | Prognosis |
|---|---|---|
| Iron deficiency | Identify blood loss; reinforce iron use; gastrointestinal referral if indicated | Usually resolves once the cause and iron stores are corrected |
| Chronic disease | Treat inflammation; monitor blood count and iron; coordinate care | Can persist while the underlying disease is active |
| Sideroblastic | Remove triggers; refer if the cause is unclear or transfusions are needed | Variable; clonal forms may require continued follow-up |
| Megaloblastic | Treat B12 or folate deficiency; monitor neurologic recovery | Counts improve; delayed B12 treatment may leave deficits |
| Aplastic | Urgent hematology; infection and bleeding precautions; discuss therapy | Depends on severity and response to treatment |
| Renal (chronic kidney disease) | Monitor hemoglobin, iron and blood pressure; refer for an erythropoiesis-stimulating agent or advanced disease | Often chronic; may improve with iron or an erythropoiesis-stimulating agent |
| Aplastic anemia (slide 55): five-year survival >75% after a bone marrow transplant from a suitable donor; most untreated patients die within one year. | ||
Fix it and it Fades (iron, megaloblastic); it Follows its disease (chronic disease, renal); it Depends (sideroblastic, aplastic).
Fades iron deficiency resolves; megaloblastic counts improve (late B12 may leave deficits)Follows chronic disease persists while active; renal often chronicDepends sideroblastic variable; aplastic depends on severity and response
| Condition | Patient education / referral | Prognosis |
|---|---|---|
| Sickle cell | Vaccines, fever and chest pain precautions, hematology follow-up | Lifelong; prevention reduces complications |
| Thalassemia | Hematology for severe forms; iron monitoring; genetic counseling | Trait often mild; severe forms need lifelong monitoring |
| G6PD deficiency | Avoid oxidative triggers; seek care for jaundice or dark urine | Usually favorable with trigger avoidance |
| Autoimmune hemolysis | Treat the cause; monitor relapse and thrombosis; hematology care | Relapse may occur; depends on cause and response |
| Hemochromatosis | Iron monitoring and phlebotomy; family screening; avoid excess iron | Early care limits injury; established cirrhosis may persist |
Shots, Genes, Triggers, Clots, Bleeds.
Shots sickle cell: vaccinesGenes thalassemia: genetic counselingTriggers G6PD: avoid oxidative triggersClots autoimmune hemolysis: watch relapse and thrombosisBleeds hemochromatosis: phlebotomy
| Grade | Description of patient |
|---|---|
| 0 | Fully active, able to carry on all predisease performance without restriction |
| 1 | Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work |
| 2 | Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours |
| 3 | Capable of only limited self-care; confined to bed or chair more than 50% of waking hours |
| 4 | Completely disabled; cannot carry on any self-care; totally confined to bed or chair |
| 5 | Dead |
| ECOG (Eastern Cooperative Oncology Group; the slide’s picture credits “Eastern Clinical Oncology Group”). Prognosis is often dictated by fitness, particularly in older patients; ECOG is frequently part of clinical trial entry criteria (slide 10). | |
Count down the day: 0 Normal, 1 Office work, 2 Self-care but no work (up more than half the day), 3 In bed more than half the day, 4 In bed all day, 5 Dead.
0 Normal fully active, no restriction1 Office no strenuous activity, light or sedentary work2 Up >50% all self-care, no work, up and about more than 50% of waking hours3 Bed >50% limited self-care, bed or chair more than 50% of waking hours4 Bed all day completely disabled5 dead
Where it breaks: The 50% line is about waking hours, and it splits 2 (up) from 3 (in bed or chair).
| Disease | Blast cut-off on the slide |
|---|---|
| Acute lymphoblastic leukemia | Defined by blast cells of lymphoid origin ≥ 20% in bone marrow (slide 25) |
| Acute myeloid leukemia | Blast cells of myeloid origin; historically ≥ 20%; new guidelines: certain genetic mutations may allow the diagnosis with only 10% or higher (slide 38) |
| Myelodysplastic syndrome | Higher risk MDS may have blasts but < 20% (otherwise AML) (slide 47) |
| CML chronic phase | No or few blasts (<5%) (slide 62) |
| CML accelerated phase | Often 10–19% blasts (slide 62) |
| CML blast phase/crisis | No number on the slide: behaves as an acute leukemia, usually AML-like (slide 62) |
| Said aloud: “20% or more for leukemias, remember that”, and the drill “10%? No. 15%? No.” She also described chronic phase as “five to 6% blast” and blast phase as “greater than 20%”: learn the slide wording; the slides give no phase for 5–9%. | |
Twenty is the line to Leukemia: at 20 it is acute leukemia, under 20 it is still MDS. CML climbs Five, Ten-to-Nineteen, then Blast.
Twenty ≥ 20% marrow blasts = ALL (lymphoid) or AML (myeloid)Under 20 higher-risk MDS (blasts < 20%)Ten (AML only) certain genetic mutations: AML at ≥ 10%Five CML chronic phase <5%Ten-to-Nineteen CML accelerated phase, often 10–19%Blast CML blast phase behaves like AML
Where it breaks: The blast phase has no number on the slide; the 5–9% gap has no phase.
| FAB | Name | What the slides add |
|---|---|---|
| M0 | Undifferentiated AML | |
| M1 | AML with minimal maturation | |
| M2 | AML with maturation | |
| M3 | Acute promyelocytic leukemia (APL) | Discussed separately: DIC, ATRA + arsenic (slide 43) |
| M4 | Acute myelomonocytic leukemia | More extramedullary involvement; gum hyperplasia (slides 33, 35) |
| M5 | Acute monocytic leukemia | More extramedullary involvement; gum hyperplasia (slides 33, 35) |
| M6 | Acute erythroid leukemia | Very rare |
| M7 | Acute megakaryocytic leukemia | Very rare (slide 33 misspells it “myelokaryocytic”) |
| FAB = French-American-British: historically ~8 subtypes; the WHO (World Health Organization) now recognizes 18 (slide 33). Out loud: “You don’t have to know anything about this, really, except that you will hear a lot about APL.” | ||
Count the cells as they mature: 0-1-2 = myeloblasts with no, little, then some maturation; 3 = Promyelocyte (APL); 4-5 = Monocytes (the Mouth: gums); 6 = Erythroid; 7 = megaKaryocyte, the last stop.
0-1-2 undifferentiated, minimal maturation, with maturation3 = Promyelocyte M3 APL4-5 = Mouth M4 myelomonocytic, M5 monocytic: extramedullary, gum hyperplasia6 = Erythroid acute erythroid leukemia, very rare7 = Last stop acute megakaryocytic leukemia, very rare
| Disease | Genetic lesion on the slide | What it means |
|---|---|---|
| Acute lymphoblastic leukemia (adults) | BCR-ABL, translocation of chromosomes 9 and 22 (Philadelphia chromosome): the most common adult mutation | Ph+ ALL: tyrosine kinase inhibitors + chemotherapy; Ph- ALL: pediatric-like regimens under 40 (slide 27) |
| Acute lymphoblastic leukemia (children) | Hyperdiploidy (excess copies of a chromosome) | Favorable prognosis |
| Acute lymphoblastic leukemia (1/3 of all ages) | No chromosome abnormalities | Need mutation analysis; relatively favorable |
| Chronic myelogenous leukemia | Hallmark BCR-ABL: fusion of chromosomes 22 and 9 → Philadelphia chromosome; BCR attaches to ABL1, a fusion protein enzyme that promotes proliferation and reduces apoptosis | PCR for BCR-ABL1 confirms the diagnosis and monitors treatment; tyrosine kinase inhibitors (slides 56–57, 60, 63) |
| Acute promyelocytic leukemia | Translocation of chromosomes 15 and 17: PML-RARA fusion | ATRA (all-trans-retinoic acid) + arsenic trioxide (slide 43) |
| Polycythemia vera | JAK2 mutation | Phlebotomy, hydroxyurea (slide 52) |
| Myelofibrosis; essential thrombocythemia | JAK-STAT pathway mutations | Myelofibrosis: JAK inhibitors (palliative); essential thrombocythemia: aspirin, hydroxyurea (slides 53–54) |
Philadelphia is a 9-to-22 Bus with two stops: ALL (adults) and CML (the hallmark). APL rides the 15-17 to the Retinoic acid bar; the MPNs ride the JAK.
9-to-22 Bus BCR-ABL, t(9;22), the Philadelphia chromosomeStop: ALL most common adult ALL mutation; TKI + chemotherapyStop: CML the hallmark; PCR confirms and monitors15-17 APL, PML-RARA; ATRA + arsenicJAK JAK2 in polycythemia vera; JAK-STAT in myelofibrosis and essential thrombocythemia
Where it breaks: Hyperdiploidy (children, favorable) and the third of ALL with no chromosome change are not in the hook.
| Polycythemia vera | Myelofibrosis | Essential thrombocythemia | |
|---|---|---|---|
| Too much | Red blood cells (blood viscosity ↑) | All mature myeloid lines, then marrow fibrosis | Platelets |
| Mutation | JAK2 | JAK-STAT; elevated cytokines | JAK-STAT; rarely inherited |
| Presentation | Fatigue, headaches, blurry vision; classic: pruritus with warm baths or showers | Fatigue; splenomegaly symptoms (pain, early satiety, bloating); night sweats, fever, weight loss | Mostly asymptomatic; clotting (headaches, fatigue, paresthesias, vision changes) or bleeding (acquired von Willebrand factor) |
| Complications | Thrombosis, splenomegaly, bleeding | Severe splenomegaly, portal hypertension, bleeding, secondary AML | Clotting: CVA (stroke), MI |
| Treatment | Phlebotomy, hydroxyurea | JAK inhibitors (palliative) | Aspirin, hydroxyurea |
| Prognosis | Excellent: ~14 years; leukemic transformation ~5% | Most aggressive: low risk 10–15 years, high risk < 2 years | Excellent: normal life span |
| Also | Hematologist; stop smoking | Hematologist at diagnosis | Hematologist; stop smoking |
Red, Scar, Plate: Polycythemia makes Red cells and Itches in the shower; Myelofibrosis Scars the marrow and swells the spleen; Thrombocythemia piles up Platelets that clot (or bleed).
Red + Itch polycythemia vera: red cells, JAK2, pruritus after warm bath; phlebotomyScar myelofibrosis: fibrosis, splenomegaly, most aggressive; JAK inhibitors palliativePlate essential thrombocythemia: platelets, clot (CVA, MI) or bleed; aspirin, hydroxyurea
Where it breaks: Hydroxyurea is in both polycythemia vera and essential thrombocythemia; the survival numbers are not in the hook.
| Phase | Blasts | Features | Share |
|---|---|---|---|
| Chronic (stable) | No or few (<5%) | Early proliferative phase; excellent prognosis | 85–90% |
| Accelerated | Often 10–19% | May have dysplastic granulocytes and fibrosis; frequently significant splenomegaly | ~4–5% |
| Blast phase/crisis | No number on the slide | Behaves as an acute leukemia, usually AML-like; unique chromosomal and mutational abnormalities; AML-like regimens, poor responses to TKIs | ~1–2% |
| Advanced CML (accelerated or blast phase) “has different considerations” (slide 63) and a median survival < 12 months (slide 65). Out loud she said chronic phase is “five to 6% blast” and blast phase “greater than 20%”: learn the slide wording. | |||
Most stay Calm: Chronic is under 5 (and 85–90% of patients); Accelerated is Ten-to-nineteen with a big spleen; Blast crisis acts like AML and shrugs off the TKI.
Calm chronic phase, <5% blasts, 85–90%, excellent prognosisTen-to-nineteen accelerated, often 10–19%, splenomegalyActs like AML blast phase: AML-like regimens, poor TKI response, 1–2%
| Milestone | Failure | Warning | Optimal | TFR |
|---|---|---|---|---|
| 3 months | N.A. | > 10% | < 10% | N.A. |
| 6 months | > 10% | 1–10% | < 1% | N.A. |
| 12 months | > 1% | 0.1–1% | < 0.1% | N.A. |
| > 18 months | > 1% | 0.1–1% | < 0.1% | < 0.01% |
| Every cell is the BCR-ABL1 level. TFR = treatment-free remission. Slide 63: major molecular response (MMR) for 2 years may allow stopping TKIs, but 50% recur; slide 66 words it “sustained major molecular remission x 2 years”. Out loud: the level is checked about every 3 months, and warning or failure means a change of TKI or a resistance-mutation test. | ||||
Ten, One, Point-one: the optimal level drops one log at each milestone (3, 6, 12 months), and Point-oh-one at 18 earns time off (TFR).
Ten 3 months: optimal < 10%One 6 months: optimal < 1%Point-one 12 and > 18 months: optimal < 0.1%Point-oh-one > 18 months: < 0.01% = treatment-free remission range
Where it breaks: Failure lags one step behind optimal (> 10% at 6 months, > 1% at 12 and > 18); there is no failure value at 3 months.
| Rai stage | Findings |
|---|---|
| 0 | Asymptomatic lymphocytosis |
| I | Lymphocytosis and lymphadenopathy |
| II | Lymphocytosis, lymphadenopathy, organomegaly* |
| III | Lymphocytosis and anemia, with or without lymphadenopathy and/or organomegaly |
| IV | Lymphocytosis and thrombocytopenia, with or without lymphadenopathy, organomegaly, and/or anemia |
| *Organomegaly = hepatomegaly and/or splenomegaly. Rai is historical, describes prognostic groups, needs no advanced imaging (physical exam and labs), and may set the indication for treatment (symptomatic disease or rapid progression). The contemporary tool is the CLL International Prognostic Index, named on the slide without its items. | |
Count down the body from the blood: 0 Lymphs, I Lumps, II Liver or spleen, III Low red cells, IV Low platelets.
0 Lymphs lymphocytosis onlyI Lumps + lymphadenopathyII Liver or spleen + organomegaly (hepatomegaly and/or splenomegaly)III Low red cells + anemia (nodes and organs optional)IV Low platelets + thrombocytopenia (anything else optional)
Where it breaks: Stages III and IV do not need the nodes or organs: anemia alone makes III, thrombocytopenia alone makes IV.
| Chronic lymphocytic leukemia | Monoclonal B lymphocytosis | |
|---|---|---|
| Absolute lymphocyte count | > 5K x 3 months, or < 5K with lymphadenopathy or other symptoms; labs: “must be >5K; often >100K” | Elevated but <5K lymphocytes |
| Nodes, organs, cytopenias, symptoms | May be present | Absent (no lymphadenopathy, organomegaly, cytopenias, or other symptoms) |
| Confirm with | Flow cytometry: clonal B cells; coexpression of CD19 and CD5; bone marrow biopsy usually not needed | — |
| Course | Rai 0–IV; Richter transformation risk | Progresses to chronic lymphocytic leukemia at 1–2% per year |
| Neither slide says where exactly 5,000 falls; slide 7’s “must be >5K” sits against slide 8’s “< 5K with lymphadenopathy”. Other differentials (slide 9): atypical lymphocytosis with infections (pertussis); Waldenström macroglobulinemia, hairy cell leukemia, lymphomas in leukemic phase (told apart by morphology and immunophenotype). | ||
Five thousand for three months, or Under five with a Finding (nodes or symptoms); no Finding under five is just MBL, which turns 1–2 a year.
Five thousand x three months ALC >5K for 3 months = chronic lymphocytic leukemiaUnder five with a Finding ALC <5K with lymphadenopathy or other symptoms = chronic lymphocytic leukemiaNo Finding under five monoclonal B lymphocytosis1–2 a year progression to chronic lymphocytic leukemia 1–2% per year
Where it breaks: Flow cytometry, CD19 and CD5 coexpression and the 100K figure are not in the hook.
| Stage | Picture caption |
|---|---|
| 1 | Localized disease; single lymph node region or single organ |
| 2 | Two or more lymph node regions on the same side of the diaphragm |
| 3 | Two or more lymph node regions above and below the diaphragm |
| 4 | Widespread disease; multiple organs, with or without lymph node involvement |
| The picture is titled “Stages of Non-Hodgkin’s Lymphoma” and is reused for Hodgkin lymphoma on slide 40: the same four stages apply to both. Staging needs imaging (usually CT or PET, slide 25). The Hodgkin treatment slide (41) adds “IIA”, “B symptoms” and “bulky”. | |
The diaphragm is the equator: One spot; Two on one side; Three on both sides; Four in the organs.
One spot single node region or single organOne side 2+ regions, same side of the diaphragmBoth sides 2+ regions above and below the diaphragmOrgans widespread, multiple organs, with or without nodes
Where it breaks: Nothing on the picture is left out; the IIA, B-symptom and bulky labels come from the Hodgkin treatment slide.
| Presentation | Treatment |
|---|---|
| Single node, non-aggressive | Radiation |
| Low-grade B-cell lymphomas | Rituximab (anti-CD20 monoclonal antibody) if treatment required, ± chemotherapy if extensive |
| Aggressive B-cell lymphomas | Multi-drug chemotherapy, e.g. R-CHOP: rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone; some get more aggressive regimens |
| T-cell lymphomas | Similar regimens (CHOP) minus rituximab: no CD20 on T cells |
| “Highly dependent on subtype and presentation.” Follicular lymphoma: frequently watch and wait, intermittent low-intensity therapy if symptomatic (slide 16). | |
R-CHOP is Really Cooking Very Dangerous Pasta; T cells skip the R.
Really rituximabCooking cyclophosphamideVery vincristineDangerous doxorubicinPasta prednisoneT cells skip the R T-cell lymphomas: CHOP without rituximab (no CD20)
Where it breaks: The hook follows the slide’s list order, not the letters of CHOP (in CHOP, H is doxorubicin and O is vincristine). Radiation for a single non-aggressive node and rituximab alone for low-grade B-cell lymphoma are not in the hook.
| Factor | Slide wording |
|---|---|
| Age | Age > 60 |
| Spread | Extranodal sites |
| Performance status | Poor (>2) performance status, ECOG (Eastern Cooperative Oncology Group) |
| Stage | Stage III or IV |
| Lab | Elevated LDH (lactate dehydrogenase) |
| Same slide: indolent lymphomas incurable but survival often 10–15+ years (risk of progression to aggressive lymphoma); aggressive lymphomas often treatable and curable with chemotherapy (the slide’s “50% cured” was corrected out loud: “more closely to 70%”), 5-year survival 60–70%; T-cell lymphomas respond less well than B-cell. | |
A-E-P-S-L: an Aged patient, Extranodal, Poorly performing, Stage III-IV, with a high LDH.
Aged age > 60Extranodal extranodal sitesPoorly performing ECOG > 2Stage III or IVLDH elevated
Where it breaks: The survival figures in the note row are not in the hook.
| Marker | Disease | Slide wording |
|---|---|---|
| t(14;18), BCL-2 | Follicular lymphoma | BCL-2 placed on chromosome 14, preventing cell death (slide 16) |
| Cyclin D1, t(11;14) | Mantle cell lymphoma | Identifies the subtype (slide 20) |
| MYC upregulation | Burkitt lymphoma | Stimulated cell growth and division (slide 31) |
| MYD88 mutation (~90%) | Lymphoplasmacytic (Waldenström) | Excess IgM → hyperviscosity (slide 18) |
| Del 13q, del 11q, trisomy 12, del 17p | Chronic lymphocytic leukemia | 80% of cases (slide 5) |
| CD19 + CD5 | Chronic lymphocytic leukemia | Coexpressed on the lymphocytes (slide 8) |
| CD15 + CD30 | Classical Hodgkin lymphoma | Expressed (slide 39) |
| H. pylori | Gastric MALT lymphoma | 2/3 of cases (slide 17) |
| Hepatitis C | Splenic marginal zone | Associated (slide 17) |
| HTLV-1 | Adult T-cell leukemia/lymphoma | Very aggressive; Caribbean, Central and South America (slide 21) |
| Epstein-Barr virus | Endemic Burkitt; Hodgkin | Endemic Burkitt strongly associated (slide 32); Hodgkin 40–50% (slide 37) |
| HIV/AIDS | Immunodeficiency-associated Burkitt | Associated (slide 32) |
Follicles at Fourteen-Eighteen keep cells alive (BCL-2); the Mantle is Eleven-Fourteen with a Crown (cyclin D1); Burkitt's MYC Makes You Climb fast; Waldenström's MYD88 makes IgM Mud (hyperviscosity).
Fourteen-Eighteen follicular, t(14;18), BCL-2 blocks cell deathEleven-Fourteen + Crown mantle cell, t(11;14), cyclin D1Makes You Climb Burkitt, MYC upregulationMud lymphoplasmacytic, MYD88, IgM hyperviscosity
Where it breaks: The CD markers, the chronic lymphocytic leukemia deletions and the infection rows are not in the hook.
| Stage | Treatment |
|---|---|
| Early stage I and IIA | Short course of chemotherapy (ABVD historically) |
| Bulky stage I or II disease, or B symptoms | Chemotherapy + radiation |
| Stage III or IV | Chemotherapy |
| ABVD | Adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine; new agents are replacing bleomycin because of pulmonary toxicities |
| Slide 41 is titled “Management of NHL” but sits in the Hodgkin section and teaches Hodgkin treatment. Relapse after first line: allogeneic stem cell transplant (slide 42). | |
Small and quiet: short chemo. Big or Burning (bulky or B symptoms): chemo plus Beams. Spread (III-IV): chemo. ABVD: A Big Vine Drops; Bleomycin hurts the lungs.
Small and quiet I and IIA: short chemotherapyBig or Burning bulky I-II or B symptoms: chemotherapy + radiationSpread III or IV: chemotherapyA Big Vine Drops doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine
Where it breaks: The transplant-at-relapse line (slide 42) is not in the hook.
| Slide wording | |
|---|---|
| What | Medical emergency: rapid tumor breakdown releases potassium, phosphorus, uric acid |
| Kidney | Acute renal failure from uric acid and calcium phosphate crystals in the renal tubules |
| Biggest risk | Hyperkalemia → arrhythmia and potential death |
| Who | Spontaneously in highly aggressive lymphoma (Burkitt); also acute lymphoblastic and acute myeloid leukemia with marked leukocytosis |
| Treat | Aggressive IV fluid hydration |
| Prevent | Anticipate in aggressive lymphoma: allopurinol (hypouricemic agent) and fluids in advance; “drink plenty of fluids and take allopurinol!” (slide 34) |
Tumor lysis spills a PUP: Potassium, Uric acid, Phosphorus. Potassium Stops the heart, the crystals Stop the kidney; Flush and Fix with fluids and allopurinol.
PUP potassium, uric acid, phosphorus releasedStops the heart hyperkalemia → arrhythmia (largest risk)Stops the kidney uric acid and calcium phosphate crystals → acute renal failureFlush and Fix aggressive IV fluids; allopurinol ahead of time
Where it breaks: Who gets it (Burkitt spontaneously; acute leukemias with marked leukocytosis) is not in the hook.
| Letter | Finding | Slide wording |
|---|---|---|
| C | Calcium (hypercalcemia) | Constipation, increased thirst, urinary frequency, nausea |
| R | Renal insufficiency | Swelling |
| A | Anemia | Fatigue, shortness of breath |
| B | Bone lesions/pain | Often back, chest, or pelvis; osteolytic “punched out” lesions (slide 48) |
| S | Bone marrow plasma cells | Picture: “Bone marrow ≥ Sixty (60%) plasmacytosis” |
| Li | Abnormal light chain ratio | Picture: “Light chains >100:1” |
| M | MRI lesion | Picture: “MRI: ≥2 lesions” |
| Diagnosis (slide 50): ≥ 10% bone marrow plasma cells or biopsy-proven plasmacytoma + 1 or more CRAB feature. SLiM = “may be asymptomatic with certain lab findings” (slide 47), while slide 52 says myeloma is “by definition a symptomatic condition”. The picture also lists amyloidosis, hyperviscosity, polyneuropathies; higher risk of infections. | ||
The CRAB is SLiM: CRAB pinches the body (Calcium, Renal, Anemia, Bone); SLiM shows on the labs (Sixty percent, Light chains 100 to 1, MRI 2 lesions).
C hypercalcemiaR renal insufficiencyA anemiaB bone lesionsSixty ≥60% marrow plasma cellsLight 100 light chain ratio >100:1MRI 2 ≥2 MRI lesions
Where it breaks: The symptoms under each CRAB letter and the “also” list (amyloidosis, hyperviscosity, polyneuropathies) are not in the hook.
| MGUS | Smoldering myeloma | Multiple myeloma | |
|---|---|---|---|
| M-protein | < 3 g/dL | > 3 g/dL AND | Monoclonal protein on serum protein electrophoresis (characteristic) |
| Bone marrow plasma cells | Clonal < 10% | 10–60% | ≥ 10% or biopsy-proven plasmacytoma |
| Myeloma-defining events | None; asymptomatic by definition | None (anemia, bone lesions, renal failure, etc.) | + 1 or more CRAB feature |
| Progression | ~1% per year | ~10% per year; some high-risk groups >50% within 2 years | Relapsing; incurable |
| Treatment | — | Typically none; early intervention for some subgroups | 3- or 4-drug regimen; autologous transplant if a candidate |
| Neither slide says where exactly 3 g/dL or 10% falls. Smoldering “10–60%” (slide 57) meets the SLiM picture’s “≥ 60%” (slide 47) at 60%. Slide 57’s “AND” is the slide’s (current International Myeloma Working Group wording: ≥3 g/dL or 10–60%). MGUS is printed “of unknown significance” on slide 56 (“undetermined” on the slide 44 picture). | |||
Three and Ten are the gates, and the speed goes up by ten: under 3 and under 10 = MGUS, creeping 1% a year; over 3 and 10–60 = smoldering, 10% a year; 10 or more plus a CRAB = myeloma.
Under 3, under 10 MGUS: M-protein <3 g/dL, plasma cells <10%1% a year MGUS progressionOver 3, 10–60 smoldering: M-protein >3 g/dL and 10–60% plasma cells10% a year smoldering progression10 + CRAB myeloma: ≥10% plasma cells (or plasmacytoma) + 1 CRAB feature
Where it breaks: The high-risk smoldering group (>50% within 2 years) and the treatment row are not in the hook.
| Stage | Criteria | Survival (mo) |
|---|---|---|
| I | β2-microglobulin <3.5 mg/L; albumin ≥3.5 g/dL and standard-risk chromosomal abnormalities and normal LDH (defined as less than ULN) | 82 |
| II | Not R-ISS stage I or III | 62 |
| III | β2-microglobulin ≥5.5 mg/L regardless of albumin levels and high-risk chromosomal abnormalities: del 17p, t(4;14) or t(14;16) and high LDH (defined as higher than ULN) | 40 |
| R-ISS = Revised International Staging System; LDH = lactate dehydrogenase; ULN = upper limit of normal. Prognostic only: “does not impact treatment decisions broadly”. Slide 50 prints the test as “beta-2 macroglobulin”; it is beta-2 microglobulin. (Current guideline note: published stage III is β2-microglobulin ≥5.5 with high-risk abnormalities or high LDH; the slide prints “and”.) | ||
3.5 and 3.5 is stage one; 5.5 with bad chromosomes and high LDH is stage three; everything in between is two.
3.5 and 3.5 stage I: β2-microglobulin <3.5 mg/L, albumin ≥3.5 g/dL, standard risk, normal LDH5.5 + bad chromosomes stage III: β2-microglobulin ≥5.5, del 17p, t(4;14) or t(14;16), high LDHIn between stage II: not I or III
Where it breaks: The survival months (82, 62, 40) are not in the hook.
| Term | What you need to know |
|---|---|
| What this card is | First the slides Prof. Ward flagged out loud (recording, 12 November); then the slides’ own emphasis (bold, asterisks, underline, the slide 26 arrow). His rule: you are tested on what is on the slide. |
| ★ Said: iron deficiency diagnosis | “You guys want to know this slide”: microcytosis, hypochromia, ↓ ferritin, ↓ transferrin saturation, ↑ total iron-binding capacity (slide 15). |
| ★ Said: chronic disease | “Want to pay attention to this slide?”: interleukin 6 → ↑ hepcidin (slide 23). |
| ★ Said: B12 vs folate | “Definitely one that you guys want to pay attention to”: homocysteine up in both; methylmalonic acid up in B12 only (slide 47). |
| ★ Said: treatment slides | Aplastic anemia treatment (slide 58); sickle cell management (slide 98); hemochromatosis treatment, therapeutic phlebotomy (slide 104); the lifespan slide (slide 105). |
| ★ Said: smears | Genetic hemolysis: upper smear = spherocytes (slide 75). G6PD: bite cells (left) and Heinz bodies (right); hemolysis is intravascular and extravascular (slides 77–78). |
| ★ Said: thalassemia labs | “Did I tell you guys to pay attention to slide 88?” (slide 88). |
| ★ Said: acute chest | “A chest x-ray is the first imaging study if you’re suspecting acute chest syndrome” (slide 94). |
| Played down | Luspatercept (slide 33): “Sorry, don’t know that drug.” Chloroquine in G6PD: “don’t just assume all anti-malarial medications carry that same risk.” |
| ★ Iron deficiency | Chronic blood loss is the most common cause in adults (slide 10); asterisked: nail bed changes (koilonychia), cheilosis, Plummer-Vinson syndrome (slide 12). |
| ★ Ferritin trap | Ferritin is an acute phase reactant: a normal or high ferritin does not exclude iron deficiency (slide 14). |
| ★ Oral iron | Ferrous sulfate; side effect constipation (bold, underlined); the orange-juice preparation line is bold (slides 18–19). |
| ★ Chronic disease | Treat the underlying condition: arrowed “most important” (slide 26). |
| ★ B12 | Pernicious anemia is the most frequent cause; burning to hands and feet; homocysteine and methylmalonic acid levels (slides 44, 45, 47). |
| ★ Hemolysis | Haptoglobin; bilirubin, haptoglobin, lactate dehydrogenase; schistocytes; jaundice (slides 66–68, 70). |
| ★ Autoimmune hemolysis | Increased risk of venous thromboembolism (slide 73). |
| ★ G6PD | Fava beans; acute hemolytic anemia on oxidative stress (slide 79). |
| ★ Thalassemia | Imbalance in expression → accumulation and precipitation of globin subunits (slide 85); iron overload (slide 87). |
| Also bold | Sideroblastic microcytosis is variable (slide 32); microcytic vs macrocytic lab lists (slide 50). |
| Term | What you need to know |
|---|---|
| Anemia | A reduction in healthy red blood cells or hemoglobin, decreasing oxygen delivery to the tissues (slide 6). |
| First steps | History and physical; complete blood count (all three cell lines, pancytopenia?); the MCV; the reticulocyte index for marrow response (slide 8). |
| All anemias | Complete blood count, reticulocyte count, reticulocyte index (slide 50). |
| Microcytic | Serum iron, transferrin saturation, total iron-binding capacity, ferritin, fecal occult blood test, urinalysis. |
| Macrocytic | B12 and folate, smear, homocysteine and methylmalonic acid; for pernicious anemia anti-intrinsic factor and anti-parietal cell antibodies, parenteral B12 trial. |
| Term | What you need to know |
|---|---|
| Causes | Chronic blood loss (gastrointestinal, menses; most common in adults); diet (vegan, tea, calcium antacids, proton pump inhibitors); malabsorption (gastric bypass, celiac sprue, food allergies); demand (pregnancy, growth in infancy or adolescence). |
| Who | 50% of anemia worldwide; ~1 million deaths a year (71% Africa and Asia). United States: men under 50 1%, women of childbearing age 10%, 9% of children 12–36 months (1/3 of them anemic); low-income families at risk. |
| Signs | Fatigue, pallor, exercise intolerance, dyspnea on exertion, smooth tongue, pica (common), koilonychia (spoon nails), cheilosis, Plummer-Vinson syndrome. |
| Differential | Anemia of chronic disease, thalassemia, lead poisoning, zinc deficiency, sideroblastic anemia. |
| Diagnosis | Microcytosis (MCV <80), hypochromia (↓ MCH); ↓ ferritin, ↓ transferrin saturation, ↑ total iron-binding capacity; microcytic hypochromic smear. Also urinalysis, fecal occult blood (stool guaiac), consider prothrombin and partial thromboplastin times. |
| Treat | The cause: oral contraceptive (consider continuous-cycle) for menses; gastrointestinal bleed → colonoscopy or endoscopy for colorectal cancer; stop anticoagulants if severe (consult cardiology). Then iron replacement. |
| Parenteral | If intolerant or refractory; over 15 minutes to 1 hour. Ferric pyrophosphate citrate (Triferic) goes in the dialysate to replace the 5–7 mg lost per hemodialysis. |
| Term | What you need to know |
|---|---|
| Cause | Any inflammatory condition: infection, autoimmune, neoplasm. Interleukin-6 → hepcidin ↑ blocks iron absorption; inflammation inhibits renal erythropoietin; direct marrow suppression. |
| Who | 2nd most common anemia; any age; older adults at increased risk (~1 million over 65 in the United States). |
| Picture | Initially resembles iron deficiency; symptoms like iron deficiency plus the causative condition. |
| Diagnosis | Same labs as iron deficiency; erythrocyte sedimentation rate and/or C-reactive protein if inflammation not apparent; ferritin normal or increased; ferritin <30 ng/mL = coexistent iron deficiency. |
| Treat | The underlying condition; erythropoietin if indicated (hemoglobin <10); maybe parenteral iron; hematology usually not needed. |
| Term | What you need to know |
|---|---|
| Who | Rare; about 2/3 males in early childhood or adolescence, 1/3 young to middle-aged females; any age. |
| Picture | Nothing specific beyond anemia; usually moderate, hematocrit 20–30%. |
| Diagnosis | Variable microcytosis; dimorphic smear (microcytic, normal and macrocytic cells); ↑ serum iron, transferrin saturation, ferritin; zinc ↑ if from copper deficiency; ring sideroblasts on marrow aspirate = defining. |
| Treat | Remove the agent; transfusion if severe; poor response to erythropoietin; occasional response to pyridoxine (50–200 mg/day); luspatercept for myelodysplastic syndrome with ring sideroblasts; hematology for diagnosis or transfusion. |
| Lead (plumbism) | Microcytic hypochromic anemia with basophilic stippling (abnormal nucleic acid collections). Sources: industrial, gasoline sniffing, lodged bullets, lead cookware, paint chips, Flint water. |
| Lead effects | Neurologic most vulnerable (irritability, behavior change, peripheral neuropathy); abdominal colic, nausea, constipation; lead line in the gums. |
| Lead treatment | Stop exposure; by lead level; severe with neurologic effects → chelation: succimer (Chemet), dimercaprol, ethylenediaminetetraacetic acid (EDTA). |
| Term | What you need to know |
|---|---|
| Macrocytic | MCV >100: megaloblastic (B12, folate) or non-megaloblastic (alcohol or drug, hypothyroidism, liver failure, marrow dysplasia; usually <115). |
| Smear | Macro-ovalocytes and hypersegmented neutrophils (slides 39–40). |
| Folate causes | Diet (impoverished, alcohol use disorder, elderly); pregnancy; proximal small bowel malabsorption; drugs: methotrexate, 5-fluorouracil, hydroxyurea, phenytoin, metformin. |
| Folate replacement | Folic acid 1 mg orally or parenterally daily for 1–2 weeks, after checking for B12 deficiency. |
| Term | What you need to know |
|---|---|
| Absorption | Peptic digestion frees B12 → intrinsic factor from parietal cells binds it → binds cubilin in the distal ileum → transcobalamin → stored in the liver (~3–4 years or more). |
| Pernicious anemia | Most frequent cause of B12 deficiency: autoimmune attack on parietal cells and/or intrinsic factor → gastric atrophy and increased gastric cancer risk. |
| Clinical | Anemia findings; glossitis, oral ulcers. Distinguishing: neurologic (dorsal and lateral cord demyelination): neuropsychiatric change, stocking-and-glove numbness, tingling, burning of the hands and feet, then unsteady gait and lost position sense; may not improve with B12. |
| Replacement | B12 1000 mcg subcutaneously or intramuscularly weekly for 3 weeks; or oral cobalamin 1000–2000 mcg daily. |
| Term | What you need to know |
|---|---|
| Kidney: order | Complete blood count, reticulocytes, ferritin and transferrin saturation; assess other causes (slide 53). |
| Kidney: treat | Correct iron deficiency; oral or intravenous iron and an erythropoiesis-stimulating agent by stage, hemoglobin and risk; monitor hemoglobin, iron and blood pressure; nephrology for advanced disease. |
| Aplastic: what | Pancytopenia from loss of hematopoietic stem cells (the defining feature). |
| Aplastic: who | Half in the first three decades (peaks in childhood and at 20–25); male:female ~1:1; 0.6–6.1 per million. |
| Aplastic: causes | Autoimmune; stem cell injury (cytotoxic drugs, chloramphenicol, ionizing radiation, benzene, pesticides); viruses; clonal (paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, acute myeloid leukemia); inherited (Fanconi anemia, childhood). |
| Aplastic: picture | Recurrent infections (neutropenia), bleeding, petechiae, purpura (thrombocytopenia), fatigue, pallor. |
| Aplastic: plan | Bone marrow biopsy required; urgent hematology/oncology; treatment = bone marrow transplant. |
| Term | What you need to know |
|---|---|
| Causes | Viral illness, medications or chemotherapy, autoimmune disease, nutrient deficits, marrow pathology. |
| Workup | Repeat complete blood count with differential, trend, peripheral smear, other cell lines. |
| Chronic care | Stop an offending drug; correct deficiencies; selected patients need G-CSF (granulocyte colony-stimulating factor). |
| Teach | Report fever or rigors promptly; monitor counts. |
| Prognosis | Transient viral leukopenia often resolves; persistent or severe neutropenia = more infection risk, may mean marrow disease. |
| Term | What you need to know |
|---|---|
| Definition | Shortened red cell survival from premature destruction. Red cell ~6 µm vs capillaries ~2 µm. |
| Red cell defenses | Deformable membrane and cytoskeleton (spectrin, ankyrin); strong redox environment; biconcave disc (~40% more surface area). |
| All hemolytic anemias | ↓ red cell life span, compensatory ↑ erythropoiesis, retention of breakdown products (iron); marrow hyperplasia and ↑ reticulocytes; extramedullary hematopoiesis (liver, spleen, lymph nodes) if severe and chronic. |
| Routes | Extravascular (more common; spleen and liver macrophages → unconjugated bilirubin); intravascular (free hemoglobin → haptoglobin; some into urine). |
| Presentation | Anemia symptoms; severe: chest pain, high-output heart failure, shock. Differentiating: jaundice, splenomegaly, joint pain, hematuria. |
| Autoimmune | Antibody against the red cell membrane; primary (de novo, almost always IgG) or secondary; transfusion reaction. Coombs positive; venous thromboembolism risk. |
| Term | What you need to know |
|---|---|
| What | Most common genetic disorder of erythrocytes (200–400 million); X-linked recessive, so generally only males are affected; carrier females generally unaffected. |
| Mechanism | No reduced glutathione → oxidative damage → Heinz bodies inside the cell; splenic macrophages bite out a chunk (bite cells); intravascular and extravascular hemolysis. |
| Prevalence | Kurdish Jews 60–70%; Sardinians 4–35%; Nigerians 22%; Thai 17%; American Black people 11–12%; Japanese and Koreans 0–1%. |
| Symptoms | None until oxidative stress; then abdominal pain, jaundice, dark urine, splenomegaly. |
| Treat | “Don’t eat that” (avoid the trigger); hydrate; transfuse if needed; splenectomy only for recurrent attacks. |
| Term | What you need to know |
|---|---|
| What | Mutations cut alpha or beta globin synthesis; most erythroblasts die in the marrow; globin imbalance → subunits precipitate → destruction in the spleen. |
| Course | Hemolytic anemia, iron overload, splenomegaly, extramedullary hematopoiesis, jaundice, skeletal changes (pictured on slide 87). |
| Treat | Supportive: transfusion only when absolutely necessary (worsens iron overload); folic acid; genetic counseling; preconception testing with a family history. |
| Term | What you need to know |
|---|---|
| Clinical | Anemia almost universal, hematocrit 15–30%; pain crises (microvascular occlusion: pain, tenderness, anxiety, tachycardia). |
| Infarction | Splenic infarct; aseptic necrosis of the femoral or humeral heads; retinopathy; kidney disease; leg ulcers; priapism; susceptibility to encapsulated bacteria. |
| Stroke | Pediatric stroke 300× unaffected children; 25% have a stroke by age 45. |
| Acute chest syndrome | Leading cause of death; often with a pain event; >10% adult mortality; infection, infarction, pulmonary or fat embolism; chest pain, fever, dyspnea, hypoxemia, pulmonary infiltrates on a chest X-ray. |
| Management | Hydroxyurea raises HbF and reduces vaso-occlusive events; vaccines and childhood penicillin prophylaxis; transfusion or exchange for selected severe events; red flags: fever, chest pain or hypoxemia, new neurologic deficit. |
| Term | What you need to know |
|---|---|
| What | Iron overload: excess deposition → oxidative stress, fibrosis, organ dysfunction; asymptomatic early. Liver, heart, joints, endocrine organs, skin. |
| Signs | Fatigue; skin bronzing (face, neck, groin, extensor forearms and lower legs); joint pain, 2nd and 3rd metacarpophalangeal joints and knees; cardiomyopathy. |
| Pearl | Pituitary iron → hypogonadotropic hypogonadism: low libido, impotence, amenorrhea, small testes, gynecomastia, less body hair. |
| Family | Consider HFE testing with elevated transferrin saturation or ferritin; offer first-degree relative screening. |
| Teach | Avoid iron supplements and excess alcohol. Early treatment prevents organ damage; assess fibrosis, monitor cirrhosis for liver cancer. |
| Term | What you need to know |
|---|---|
| What this card is | First what Prof. Gannon flagged out loud (recording, 18 November); then the slides’ own emphasis (bold, underline). She gave few explicit cues and no “on the exam” line. |
| ★ Said: Auer rods | “Highlight, star, underline ... Auer rods ... pathognomonic for AML” (slides 31, 36). Auer rods are fused lysosomes; they confirm a myeloid leukemia. |
| ★ Said: 20% blasts | “Write this down ... 20% or greater blast in the bone marrow” diagnoses leukemia (slides 25, 38); MDS blasts stay < 20% (slide 47). |
| ★ Said: BCR-ABL in ALL | “Star, highlight, underline ... ALL is associated with this BCR-ABL mutation ... chromosome nine and 22” (slide 20). |
| ★ Said: Reed-Sternberg | “If you’re ever taking a test and you see a Reed Sternberg cell ... Hodgkin lymphoma” (slide 15). |
| ★ Said: B symptoms | “Make sure you’re writing down what are B symptoms”: fevers, night sweats, weight loss (slides 15, 22). |
| ★ Said: hematopoiesis | “Ingrain this in your brains”: stem cell → myeloid (megakaryocyte/platelets, eosinophil, basophil, erythrocytes, monocyte, neutrophil) and lymphoid (T, B, NK; B → plasma cell) (slide 5). |
| ★ Said: ALL | Bimodal: children, then older adults (slide 18); lumbar puncture, “the big one”: CNS leukemia is common in ALL (slides 23, 25). |
| ★ Said: APL | “Bleeding, DIC, coagulopathy, and that it does not need chemotherapy. ATRA and arsenic” (slide 43). |
| ★ Said: tests | Bone marrow biopsy and flow cytometry = “your backbone testing” (slide 36). JAK2 in polycythemia vera, “you may come across this on your testing” (slide 52). ECOG matters for treatment (slide 10). |
| ★ Said: CML milestones | Optimal BCR-ABL1 < 10% at 3 months, < 1% at 6, < 0.1% at 12 (slide 64). |
| Played down | FAB subtypes except APL (slide 33); secondary-AML subgroup modifiers (slide 38); protocol pictures (slides 26, 39, a joke); flow markers; TKI side effects (slide 63). |
| Slides underline | Bone marrow biopsy and/or flow cytometry (slides 11, 23, 36); most common malignancy under 15 = ALL (slide 18); Auer rods confirm myeloid etiology (slide 36); splenomegaly in CML (slide 59); bone marrow biopsy and PCR for BCR-ABL1 (slide 60). |
| Slides bold | Ph+ ALL = TKI + chemotherapy (slide 27); secondary AML = poor outcome (slides 32, 38); gum involvement in M4/M5 (slide 35); fit 7+3 vs unfit low-intensity, allogeneic transplant IF remission (slide 40); MDS: ESA for low risk + anemia, only cure = allogeneic transplant (slide 48); PV pruritus with warm baths (slide 52); ET aspirin, hydroxyurea (slide 54); CML now largely chronic (slide 56). |
| Term | What you need to know |
|---|---|
| Clonality | One oncogenic mutation in a single somatic cell gives a clonal advantage; the clone expands and gathers more alterations (slide 6). |
| Definition | Cancers of blood-forming tissues or the lymphatic system from a monoclonal hematologic clone; leukemias, lymphomas, plasma cell disorders; cell of origin sets the type (lymphoid or myeloid) (slide 7). |
| Acute vs chronic | Acute = immature progenitor white cells, rapid proliferation; chronic = mature malignant white cells. Crowding causes anemia, thrombocytopenia, most commonly leukocytosis (slide 14). |
| Lymphoma | Lymphoid tissue (nodes, spleen, thymus); >100 subtypes; non-Hodgkin 90% (B and T cell), Hodgkin 10% (few Reed-Sternberg cells among immune cells); lymphadenopathy, night sweats, weight loss, fevers (slide 15). |
| Myeloma | Plasma cells (terminally differentiated B cells); one monoclonal antibody, the M protein; CRAB: hypercalcemia, renal dysfunction, anemia, bone pain; infections (slide 16). |
| Epidemiology | 9.4% of new United States cancers (2025); ~1.8 million living with one; 9.1% of cancer deaths (slide 8). |
| Risk factors | Radiation, benzene; family history, trisomies; autoimmune disorders; older age (exceptions: ALL, some lymphomas) (slide 9). |
| Presentation | Non-specific: fatigue (anemia), bleeding (thrombocytopenia), swollen nodes (lymphoma), bone pain (myeloma); incidental cytopenias or high protein (myeloma). Almost all need bone marrow biopsy and/or flow cytometry (slide 11). |
| Transplant | HSCT = bone marrow transplant, after high-dose chemotherapy +/- radiation. Allogeneic = donor cells; autologous = own cells (“stem cell rescue”) (slide 12). |
| Term | What you need to know |
|---|---|
| What | Lymphoid progenitor/stem cell leukemia; very immature, rapidly proliferating; B-cell precursor (leukemic, marrow) or T-cell (rarer, lymphoma-like, thymus, mediastinal mass); lymphoblastic lymphoma subtype (slides 18–19, 22). |
| Who | Bimodal: most common malignancy under 15 (5-year survival >90%); adult peak ~50, poor over 40. Slide 21: children under 5, adults over 50; male (slides 18, 21). |
| Risk factors | Radiation (atomic bomb, prior treatment); benzene, chemotherapy; EBV, HTLV-1 (Caribbean); Down syndrome, Fanconi anemia; male (slide 21). |
| Genetics | Children: hyperdiploidy, favorable. Adults: BCR-ABL t(9;22) (Philadelphia). 1/3: no chromosome change, relatively favorable (slide 20). |
| Signs | Anemia, bleeding (petechiae, purpura), infections, B symptoms, >50% lymphadenopathy/hepatomegaly/splenomegaly, bone or joint pain. White count often > 30K (30% neutropenic) (slide 22). |
| Diagnose | Flow cytometry (B or T) + bone marrow biopsy; imaging, labs, lumbar puncture. Lymphoid blasts ≥ 20% in marrow; diffuse marrow and blood involvement (aggressive lymphomas spare the marrow); CNS involvement = adverse (slides 23, 25). |
| Differential | AML, CLL, aggressive lymphomas, hairy cell leukemia; lymphoblastic lymphoma (treated alike); atypical lymphocytosis of mononucleosis, pertussis (not clonal on flow) (slide 24). |
| Treat | Ph-: pediatric-like regimens under 40 (induction, consolidation, maintenance). Ph+: TKI + chemotherapy. Allogeneic transplant for adverse risk or relapse (slide 27). |
| Outcome | Under 15: ~90% five-year survival, 2–5 years of chemotherapy; adults ~40%. Hematologist/oncologist, admission, life-long surveillance, trials (slides 28–29). |
| Term | What you need to know |
|---|---|
| What | Myeloid progenitor/stem cell leukemia; Auer rods pathognomonic; mostly over 60; unusual in children outside neonates (slide 31). |
| Risk groups | Favorable, intermediate, poor. Secondary AML (from MDS, MPN, or after other cancer therapy) = poor outcomes (slides 32, 38). |
| Risk factors | Prior high-dose radiation; benzene, petroleum, alkylators; HIV; Down syndrome, Fanconi anemia; over 60; male (slide 34). |
| Signs | Anemia, bleeding, infections, B symptoms; M4/M5: gum hyperplasia, extramedullary disease. White count usually high; > 200K rare; > 100K = emergent leukapheresis (slides 33, 35). |
| Diagnose | Flow cytometry (vs ALL) + bone marrow biopsy; Auer rods confirm myeloid; mutation sequencing. Myeloid blasts ≥ 20% (10% with certain mutations) (slides 36, 38). |
| Differential | ALL, CML, MDS, myeloproliferative disorders; pancytopenia of infection, aplastic anemia, nutritional deficiency, drugs (slide 37). |
| Treat | Fit: 7+3 (cytarabine + anthracycline). Unfit: hypomethylating agents +/- venetoclax (BCL-2 inhibitor). Allogeneic transplant for intermediate/high risk once in remission (slide 40). |
| Outcome | Relapse common; 48% at 1 year, 25–30% at 5; favorable risk ~2/3; over 70: 5%; adverse or secondary ~10% (slide 41). |
| APL (M3) | Arrest at the promyelocyte; t(15;17) PML-RARA; DIC and bleeding, high early mortality; arsenic trioxide + ATRA; >90% cure if the presentation is survived (slide 43). |
| Term | What you need to know |
|---|---|
| What | Myeloid malignancies defined by dysplasia (abnormal-appearing myeloid cells); from clonal hematopoiesis; hypercellular marrow, cells not functional (slides 45–46). |
| Who | Older (median 70), men; often idiopathic; sometimes prior chemotherapy or radiation (slide 46). |
| Picture | Cytopenias, most often anemia; many asymptomatic, found incidentally; abnormal neutrophils; multinucleated red cells; higher risk: blasts < 20% (otherwise AML) (slide 47). |
| Treat | Low risk + anemia: ESA (erythropoiesis-stimulating agents) + transfusions; neutropenia: myeloid growth factors (careful); higher risk: chemotherapy or hypomethylating agents; only cure = allogeneic transplant (slide 48). |
| Outcome | Lower risk: median survival > 5 years. Very high risk: median overall survival 9 months, > 80% AML within 5 years. Low risk goal: quality of life (slide 49). |
| Term | What you need to know |
|---|---|
| What | Rare myeloid malignancies with atypical proliferation of mature cell lines (slide 51). |
| Polycythemia vera | JAK2; red cells ↑, viscosity ↑; fatigue, headaches, blurry vision; pruritus with warm baths or showers; thrombosis, splenomegaly, bleeding; phlebotomy, hydroxyurea; ~14 years, ~5% leukemic; hematologist, stop smoking (slide 52). |
| Myelofibrosis | JAK-STAT, cytokines ↑, all myeloid lines ↑, then marrow fibrosis; splenomegaly (pain, early satiety, bloating), night sweats, fever, weight loss; most aggressive MPN; portal hypertension, secondary AML; JAK inhibitors, palliative; 10–15 years low risk, < 2 high risk (slide 53). |
| Essential thrombocythemia | JAK-STAT; platelets ↑; mostly asymptomatic; clotting (headache, paresthesias, vision changes) or bleeding from acquired von Willebrand factor loss; CVA, MI; aspirin, hydroxyurea; normal life span; stop smoking (slide 54). |
| Term | What you need to know |
|---|---|
| What | Stem cell leukemia making excess granulocytes (more mature than blasts); historically to acute leukemia in ~4–6 years; BCR-ABL / Philadelphia chromosome hallmark; now largely chronic (slide 56). |
| Mechanism | t(9;22): BCR attaches to ABL1; the fusion enzyme drives proliferation, blocks apoptosis: the cell “can’t turn off” (slide 57). |
| Who | 15–20% of leukemias; median age 45–55; slightly more men; radiation bomb victims; no other risk factors (slide 58). |
| Signs | ~50% asymptomatic (leukocytosis on a blood count); fatigue; splenomegaly (abdominal swelling); B symptoms. White count often > 100K (to 500K), platelets high, anemia, very low blasts (slide 59). |
| Diagnose | Bone marrow biopsy + PCR for BCR-ABL1; PCR in a patient with marked granulocytosis confirms and later monitors; marrow: granulocytic proliferation, myelocytes (slide 60). |
| Differential | Myelofibrosis (CML: normal red cell shape, normal hematocrit; BCR/ABL1+). Reactive leukocytosis: no splenomegaly, white count usually < 50K, BCR/ABL1 negative (slide 61). |
| Treat | Tyrosine kinase inhibitors (6 agents) for chronic phase; stop after MMR for 2 years (50% recur, most recapture); allogeneic transplant for young healthy patients with TKI resistance or advanced disease (slides 63, 65). |
| Outcome | Most live normal lives on TKIs; accelerated or blast phase median survival < 12 months; hematologist; treatment for life unless sustained remission x 2 years; trials for advanced phase (slides 65–66). |
| Term | What you need to know |
|---|---|
| Children | ALL: most common malignancy under 15, peak under 5, hyperdiploidy favorable, ~90% survive; AML unusual outside neonates (slides 18, 20–21, 28, 31). |
| Adults | ALL second peak ~50, poor over 40; CML median 45–55 (slides 18, 58). |
| Elderly | Fitness (ECOG) drives prognosis; AML over 60, unfit → low-intensity therapy, over 70 only 5% at 5 years; MDS median 70 (slides 10, 31, 40–41, 46). |
| Term | What you need to know |
|---|---|
| ★ Said: CRAB | “You absolutely need to know this ... it will 100% be on a test”: hypercalcemia, renal insufficiency, anemia, bone lesions (slide 47). |
| ★ Said: 10% plasma cells | Myeloma needs only ≥10% marrow plasma cells (+ 1 CRAB), unlike the 20% blasts of acute leukemia: “remember that for your test” (slide 50). Remember Bence Jones protein. |
| ★ Said: Burkitt | “Starry sky, you think Burkitt’s ... you’ll definitely see that on a test”; endemic = sub-Saharan Africa, “strongly, strongly, strongly associated with EBV” (slide 32). |
| ★ Said: Hodgkin | Reed-Sternberg cells = “automatically think of Hodgkin’s” (slide 36); ABVD = Hodgkin (slide 41); node pain after alcohol (slide 38). |
| ★ Said: tumor lysis | “A medical emergency ... you need to recognize it for your testing”: high potassium, phosphorus, uric acid (she added low calcium); fluids + allopurinol (slide 28). |
| ★ Said: CLL | High white count + painless nodes = think CLL; flow cytometry is the key test, CD19 + CD5 pathognomonic, so no marrow biopsy (slides 7–8); Richter transformation (slide 12); “an isolated white count alone does not equal treatment”. |
| ★ Said: lymphoma | Infections to know: HIV, EBV, HTLV-1, H. pylori (slide 23); excisional biopsy, never trust a negative fine needle aspiration; LDH on every lymphoma (slide 25); stage by the diaphragm (slide 26); T cells worse than B cells (slide 30). |
| Played down | CD numbers beyond CD19/CD5; follicular t(14;18)/BCL-2; nodal and splenic marginal zone; mantle cell; Lyme and HHV-8; myeloma staging. Still on the slides. |
| ★ Chronic lymphocytic leukemia | Mature B cells (slide 4); frequently diagnosed while asymptomatic, painless lymphadenopathy, lymphocytosis >5K (slide 7); confirmed by flow cytometry, no marrow biopsy usually (slide 8); watch and wait (slide 11); Richter transformation (slide 12). |
| ★ Non-Hodgkin | 85% B-cell, aggressive to indolent (slide 15); excisional biopsy and CT or PET (slide 25); tumor lysis syndrome: emergency, aggressive IV fluids (slide 28); poor-prognosis factors (slide 30). |
| ★ Burkitt | “Starry sky” (slide 32); prompt treatment, emergent referral; excellent prognosis if found early; tumor lysis (slide 33). |
| ★ Hodgkin | Reed-Sternberg cells (slide 36); bimodal, Epstein-Barr virus 40–50% (slide 37); painless cervical nodes (70%), pain with alcohol (slide 38); treatment by stage (slide 41); >90% alive at 5 years (slide 42). |
| ★ Myeloma | CRAB (slide 47); ≥10% plasma cells or plasmacytoma + 1 CRAB (slide 50); goal = prolonged remissions (slide 52); 3- or 4-drug regimen, most relapse (slide 53); shorter remissions each line, incurable (slide 54); smoldering 10% per year (slide 57). |
| Term | What you need to know |
|---|---|
| What | Proliferative leukemia of mature B-cell lymphocytes in blood, marrow, nodes, spleen (same disease as small lymphocytic lymphoma); 1% of United States cancers. Mature T-cell form: T-cell prolymphocytic leukemia. |
| Genes | 80%: del 13q, del 11q, trisomy 12, del 17p. |
| Who | Median age 70; 2× males; Eastern European and Jewish descent; no known occupational or environmental risk factors. |
| Picture | Often asymptomatic, routine labs; painless firm mobile nodes (50–90%); B symptoms 5–10%; fatigue, bruising, infections; splenomegaly ~40%. |
| Diagnosis | Flow cytometry; ALC >5K x 3 months (or <5K with nodes/symptoms); CD19 + CD5; cytogenetics for prognosis; marrow biopsy usually not needed; Rai stage. |
| Treat | Watch and wait until lymphocyte doubling <6 months or symptoms. BTK inhibitors (Bruton tyrosine kinase: ibrutinib, acalabrutinib, zanubrutinib; continuous); venetoclax (BCL-2) + antibody (fixed duration); rituximab, obinutuzumab, ofatumumab. |
| Outlook | 5-year relative survival ~88%; Richter transformation to aggressive B-cell lymphoma; many die with it, not from it; hematology/oncology, outpatient, pill (indefinite) or infusion + pill (time-limited). |
| Term | What you need to know |
|---|---|
| Group | Lymphoid malignancy of B (85%), T or NK cells; 4% of United States cancers; very aggressive (Burkitt, diffuse large B-cell, T-cell leukemia/lymphoma) to indolent (follicular, marginal zone, chronic lymphocytic leukemia). |
| Follicular | Most common indolent; waxing and waning painless nodes; t(14;18) BCL-2; packed follicles; often watch and wait; incurable. |
| Marginal zone | 5–17%; MALT most common (gut, eyes, lungs); gastric MALT 2/3 H. pylori; splenic = hepatitis C; older adults. |
| Lymphoplasmacytic | = Waldenström macroglobulinemia; MYD88 ~90%; IgM → hyperviscosity (blurred vision, headache, rarely stroke); 5-year 78%; familial, farming, pesticides. |
| Diffuse large B-cell | Most common non-Hodgkin lymphoma in adults; fast-growing mass and/or B symptoms; often curable (slide 34’s cure figure corrected out loud upward). |
| Mantle cell | Rare (5%); cyclin D1 t(11;14); aggressive; men 60–70; survival <2 to >9 years. |
| T-cell | Peripheral T-cell, not otherwise specified = most common (1/3); adult T-cell leukemia/lymphoma: HTLV-1, Caribbean, Central and South America; NK/T-cell: nasal. |
| Mycosis fungoides | Skin lesions like a fungal infection → nodules that may ulcerate; Sézary syndrome = erythroderma with severe itch; treat the skin. |
| Term | What you need to know |
|---|---|
| Risk | White, developed countries, male; immunosuppression, transplant; lupus, Sjögren, celiac, Crohn’s; DDT (farming); H. pylori, HTLV-1, hepatitis C, HIV, Epstein-Barr virus, Lyme, HHV-8; family history. |
| Picture | Peripheral nodes >2/3; B symptoms; pruritus, rash; extranodal in about half (CNS lymphoma: headache, neuro deficits); mediastinal B-cell: mass, cough, abnormal chest X-ray. |
| Diagnosis | Excisional lymph node biopsy (2 cm, persistent, growing); not fine needle aspiration (architecture); CT or PET; CBC, chemistries (tumor lysis), LDH; marrow biopsy; lumbar puncture for high-grade incl. Burkitt. |
| Chemo harms | Infections, bleeding, anemia, electrolyte abnormalities, diarrhea (all agents). |
| Teach | Hematologist, ideally a lymphoma expert; outpatient unless aggressive with electrolyte problems; Burkitt: rapid transfer; fluids + allopurinol. |
| Term | What you need to know |
|---|---|
| What | Very aggressive; MYC upregulation; very rapidly growing, often painless swelling (visible change within a day); B symptoms. |
| Three types | Endemic: sub-Saharan Africa, New Guinea, Epstein-Barr virus. Sporadic: United States, Western Europe, males, almost always <35. Immunodeficiency: HIV/AIDS. |
| Pathology | “Starry sky”: sheets of lymphoma with benign macrophages clearing dying cells. |
| Act | Prompt treatment, emergent hematology referral; doubling within 24 hours; multi-agent chemotherapy; watch for tumor lysis; lumbar puncture in work-up. |
| Outlook | Excellent if early: >90% children, 50–90% adults. |
| Term | What you need to know |
|---|---|
| What | B-cell lymphoma: few Reed-Sternberg cells (binucleated, neoplastic B cells) among many immune cells; contiguous, orderly spread; 10–15% of lymphomas. |
| Who | Bimodal: 20s and >60; same-sex sibling 10×; Epstein-Barr virus 40–50%; HIV, HHV-6, tuberculosis. |
| Picture | Painless asymptomatic nodes (70%), usually cervical (supraclavicular, mediastinal); pain with alcohol; mediastinal mass on chest X-ray; splenomegaly ~30%; intense pruritus. |
| Diagnosis | Excisional biopsy, not fine needle aspiration; CD15 and CD30; chest X-ray; CBC, chemistries, LDH; marrow biopsy; Lugano stage. |
| Outlook | >90% alive at 5 years; relapse → allogeneic stem cell transplant; worse: older, bulky, lymphocyte-depleted or mixed cellularity; late myelodysplastic syndrome, secondary leukemia, other cancers. |
| Term | What you need to know |
|---|---|
| What | Plasma cell (terminally differentiated B cell) clone making one antibody, most commonly IgG; 10% of hematologic malignancies; spectrum MGUS → smoldering → myeloma. |
| Mechanism | Osteoclast activation → calcium release; kidney injury from light chain and calcium phosphate deposition; anemia from kidney and marrow. |
| Who | Most over 65; African Americans higher risk; family history; prior MGUS or smoldering myeloma; radiation, chemical, occupational. |
| Picture | CRAB; infections; skull “punched out” lytic lesions. |
| Differential | Smoldering myeloma, MGUS; Waldenström (IgM); chronic lymphocytic leukemia, non-Hodgkin lymphoma, amyloidosis; reactive hypergammaglobulinemia (cirrhosis, inflammation). |
| Work-up | M-protein on serum protein electrophoresis; urine Bence Jones protein; CBC, metabolic panel; 24-hour urine protein electrophoresis; marrow biopsy with flow; kappa/lambda ratio; beta-2 microglobulin; whole-body CT. |
| Treat | Goal: prolonged remissions, survival, quality of life. Proteasome inhibitor + immunomodulatory drug + steroid (3–4 drugs); autologous transplant + maintenance if a candidate; continuous therapy at relapse; CAR-T, bispecifics for relapse. |
| Outlook | 5-year relative survival ~60%; shorter remission each line; incurable; may exceed 10 years today; lifelong follow-up with a myeloma expert. |